{"analyses":[{"ciLowerLimit":"0.330","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.864","estimateComment":"Calculated by Cox proportional hazard model","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0096","paramType":"Hazard Ratio (HR)","paramValue":"0.534","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events","groupId":"OG000","lowerLimit":"108.3","upperLimit":"NA","value":"128.1"},{"groupId":"OG001","lowerLimit":"55.9","upperLimit":"157.3","value":"89.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"88"}],"units":"Participants"}],"description":"Maximum duration of RBC transfusion independence for participants who achieve RBC-TI ≥ 84 days.","dispersionType":"95% Confidence Interval","groups":[{"description":"Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg.","id":"OG000","title":"Luspatercept"},{"description":"Starting dose of 450 IU/kg (maximum total starting dose is 40,000 IU) subcutaneous injection once every week (7 days; QW). Dose levels can be increased in a stepwise manner beyond the starting dose to 787.5 IU/kg, and up to a maximum of 1,050 IU/kg (with a maximum total dose of 80,000 IU).","id":"OG001","title":"Epoetin Alfa"}],"paramType":"MEDIAN","populationDescription":"ITT Population (all randomized participants regardless of whether or not the participant received treatment) who were RBC-TI \\>= 12 Weeks (Week 1-24) responders","reportingStatus":"POSTED","timeFrame":"Week 1 through End of Treatment (Up to approximately an average of 66 weeks and a maximum of 202 weeks)","title":"Duration of Red Blood Cell Transfusion Independence (RBC-TI) ≥ 12 Weeks (84 Days)","type":"SECONDARY","unitOfMeasure":"Weeks"}